Page 1512 - Hematology_ Basic Principles and Practice ( PDFDrive )

1342.e2 Part VII Hematologic Malignancies

treated on Children’s Oncology Group trial A5971: a report from the 61. Fujita N, Kobayashi R, Takimoto T, et al: Results of the Japan Asso-
Children’s Oncology Group. Pediatr Blood Cancer 59:1229, 2012. ciation of Childhood Leukemia Study (JACLS) NHL-98 protocol for
41. Termuhlen AM, Smith LM, Perkins SL, et al: Disseminated lympho- the treatment of B-cell non-Hodgkin lymphoma and mature B-cell
blastic lymphoma in children and adolescents: results of the COG acute lymphoblastic leukemia in childhood. Leuk Lymphoma 52:223,
A5971 trial: a report from the Children’s Oncology Group. Br J 2011.
Haematol 162:792, 2013. 62. Gerrard M, Cairo MS, Weston C, et al: Excellent survival following
42. Reiter A, Schrappe M, Tiemann M, et al: Improved treatment results two courses of COPAD chemotherapy in children and adolescents with
in childhood B-cell neoplasms with tailored intensification of therapy: resected localized B-cell non-Hodgkin’s lymphoma: results of the FAB/
a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. LMB 96 international study. Br J Haematol 141:840, 2008.
Blood 94:3294, 1999. 63. Pillon M, Di Tullio MT, Garaventa A, et al: Long-term results of the
43. Burkitt D: A children’s cancer dependent on climatic factors. Nature first Italian Association of Pediatric Hematology and Oncology protocol
194:232, 1962. for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP
44. Swerdlow SH, Webber SA, Chadburn A, et al: Classification of tumours LNH92). Cancer 101:385, 2004.
of haematopoietic and lymphoid tissues, Lyon, France, 2008, IARC Press. 64. Hill QA, Owen RG: CNS prophylaxis in lymphoma: who to target and
45. Gutierrez MI, Bhatia K, Barriga F, et al: Molecular epidemiology of what therapy to use. Blood Rev 20:319, 2006.
Burkitt’s lymphoma from South America: differences in breakpoint 65. Meinhardt A, Burkhardt B, Zimmermann M, et al: Phase II window
location and Epstein-Barr virus association from tumors in other world study on rituximab in newly diagnosed pediatric mature B-cell non-
regions. Blood 79:3261, 1992. Hodgkin’s lymphoma and Burkitt leukemia. J Clin Oncol 28:3115,
46. Karajannis MA, Hummel M, Oschlies I, et al: Epstein-Barr virus infec- 2010.
tion in Western European pediatric non-Hodgkin lymphomas. Blood 66. Goldman S, Smith L, Anderson JR, et al: Rituximab and FAB/LMB
102:4244, 2003. 96 chemotherapy in children with stage III/IV B-cell non-Hodgkin
47. Salaverria I, Martin-Guerrero I, Wagener R, et al: A recurrent 11q lymphoma: a Children’s Oncology Group report. Leukemia 27:1174,
aberration pattern characterizes a subset of MYC-negative high-grade 2013.
B-cell lymphomas resembling Burkitt lymphoma. Blood 123:1187, 67. Goldman S, Smith L, Galardy P, et al: Rituximab with chemotherapy
2014. in children and adolescents with central nervous system and/or bone
48. Poirel HA, Cairo MS, Heerema NA, et al: Specific cytogenetic abnor- marrow-positive Burkitt lymphoma/leukaemia: a Children’s Oncology
malities are associated with a significantly inferior outcome in children Group report. Br J Haematol 167:394, 2014.
and adolescents with mature B-cell non-Hodgkin’s lymphoma: results 68. Reiter A, Klapper W: Recent advances in the understanding and man-
of the FAB/LMB 96 international study. Leukemia 23:323, 2009. agement of diffuse large B-cell lymphoma in children. Br J Haematol
49. Nelson M, Perkins SL, Dave BJ, et al: An increased frequency of 13q 142:329, 2008.
deletions detected by fluorescence in situ hybridization and its impact 69. Oschlies I, Klapper W, Zimmermann M, et al: Diffuse large B-cell
on survival in children and adolescents with Burkitt lymphoma: results lymphoma in pediatric patients belongs predominantly to the germinal-
from the Children’s Oncology Group study CCG-5961. Br J Haematol center type B-cell lymphomas: a clinicopathologic analysis of cases
148:600, 2010. included in the German BFM (Berlin-Frankfurt-Münster) Multicenter
50. Love C, Sun Z, Jima D, et al: The genetic landscape of mutations in Trial. Blood 107:4047, 2006.
Burkitt lymphoma. Nat Genet 44:1321, 2012. 70. Burkhardt B, Zimmermann M, Oschlies I, et al: The impact of age
51. Richter J, Schlesner M, Hoffmann S, et al: Recurrent mutation of the and gender on biology, clinical features and treatment outcome of
ID3 gene in Burkitt lymphoma identified by integrated genome, exome non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol
and transcriptome sequencing. Nat Genet 44:1316, 2012. 131:39, 2005.
52. Schmitz R, Young RM, Ceribelli M, et al: Burkitt lymphoma patho- 71. Miles RR, Raphael M, McCarthy K, et al: Pediatric diffuse large B-cell
genesis and therapeutic targets from structural and functional genomics. lymphoma demonstrates a high proliferation index, frequent c-Myc
Nature 490:116, 2012. protein expression, and a high incidence of germinal center subtype:
53. Sandlund JT, Downing JR, Crist WM: Non-Hodgkin’s lymphoma in report of the French-American-British (FAB) international study group.
childhood. N Engl J Med 334:1238, 1996. Pediatr Blood Cancer 51:369, 2008.
54. Mbulaiteye SM, Biggar RJ, Bhatia K, et al: Sporadic childhood Burkitt 72. Lim MS, Beaty M, Sorbara L, et al: T-cell/histiocyte-rich large B-cell
lymphoma incidence in the United States during 1992-2005. Pediatr lymphoma: a heterogeneous entity with derivation from germinal
Blood Cancer 53:366, 2009. center B cells. Am J Surg Pathol 26:1458, 2002.
55. Leucci E, Cocco M, Onnis A, et al: MYC translocation-negative clas- 73. Bea S, Zettl A, Wright G, et al: Diffuse large B-cell lymphoma sub-
sical Burkitt lymphoma cases: an alternative pathogenetic mechanism groups have distinct genetic profiles that influence tumor biology and
involving miRNA deregulation. J Pathol 216:440, 2008. improve gene-expression-based survival prediction. Blood 106:3183,
56. Salaverria I, Zettl A, Bea S, et al: Chromosomal alterations detected by 2005.
comparative genomic hybridization in subgroups of gene expression- 74. Mestre C, Rubio-Moscardo F, Rosenwald A, et al: Homozygous dele-
defined Burkitt’s lymphoma. Haematologica 93:1327, 2008. tion of SOCS1 in primary mediastinal B-cell lymphoma detected by
57. Patte C, Auperin A, Michon J, et al: The Societe Francaise d’Oncologie CGH to BAC microarrays. Leukemia 19:1082, 2005.
Pediatrique LMB89 protocol: highly effective multiagent chemotherapy 75. Seidemann K, Tiemann M, Lauterbach I, et al: Primary mediastinal
tailored to the tumor burden and initial response in 561 unselected large B-cell lymphoma with sclerosis in pediatric and adolescent
children with B-cell lymphomas and L3 leukemia. Blood 97:3370, patients: treatment and results from three therapeutic studies
2001. of the Berlin-Frankfurt-Münster Group. J Clin Oncol 21:1782,
58. Cairo MS, Gerrard M, Sposto R, et al: Results of a randomized inter- 2003.
national study of high-risk central nervous system B non-Hodgkin 76. Steinfeld R, Grapp M, Kraetzner R, et al: Folate receptor alpha defect
lymphoma and B acute lymphoblastic leukemia in children and causes cerebral folate transport deficiency: a treatable neurodegenerative
adolescents. Blood 109:2736, 2007. disorder associated with disturbed myelin metabolism. Am J Hum Genet
59. Woessmann W, Seidemann K, Mann G, et al: The impact of the 85:354, 2009.
methotrexate administration schedule and dose in the treatment of 77. Dunleavy K, Pittaluga S, Maeda LS, et al: Dose-adjusted EPOCH-
children and adolescents with B-cell neoplasms: a report of the BFM rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J
Group Study NHL-BFM95. Blood 105:948, 2005. Med 368:1408, 2013.
60. Patte C, Auperin A, Gerrard M, et al: Results of the randomized inter- 78. Woessmann W, Lisfeld J, Burkhardt B: Therapy in primary mediastinal
national FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin B-cell lymphoma. N Engl J Med 369:282, 2013.
lymphoma in children and adolescents: it is possible to reduce treatment 79. Woessmann W, Seidemann K, Mann G, et al: The impact of the
for the early responding patients. Blood 109:2773, 2007. methotrexate administration schedule and dose in the treatment of